文献速递慢性肾脏病遗传性与小管间质肾病

CKD G4-5D 患者 CKD 相关骨质疏松的实用治疗策略

CKD-associated osteoporosis in patients with CKD G4-5D: a pragmatic treatment approach.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

该综述聚焦 CKD G4-5D 患者骨折风险显著升高的临床问题,基于 2023 年 KDIGO 提出的「CKD 相关骨质疏松」概念,梳理现有治疗标准与病理生理、诊断及管理新进展,提出序贯治疗思路和实用治疗流程,并强调需随机对照试验在晚期 CKD 中验证疗效。

要点

  • CKD G4-5D 患者骨折风险较同龄同性别肾脏健康人群高数倍。
  • 治疗前应先优化矿物质代谢,包括针对甲状旁腺激素的治疗。
  • 生活方式干预为低风险/潜在高回报措施,应推荐给所有患者。

核心结论

  • CKD 相关骨质疏松的治疗需在了解 CKD 的基础上个体化,现有证据支持先优化矿物质代谢再启动骨靶向药物的序贯策略。
  • 生活方式干预应作为所有患者的低风险/潜在高回报措施予以考虑。
  • 尚需设计良好、把握度充分的随机对照试验确认或否定晚期 CKD 中治疗的获益。

研究设计与样本

  • 综述,总结 CKD 相关骨质疏松的现有治疗标准,并讨论病理生理、诊断、结局预测和管理的新进展。
  • 提出一个实用的治疗流程,等待更明确的临床试验证据。

主要发现

  • 随着 CKD 进展至 G4-5D,骨折风险较年龄和性别匹配的肾脏健康背景人群高数倍。
  • 2023 年 KDIGO 引入「CKD 相关骨质疏松」术语,强调 CKD 与其他骨质疏松在诊断评估和治疗选择上的重叠,同时需结合 CKD 知识个体化治疗。

关键数值与推荐

  • 现有证据支持序贯治疗:先优化矿物质代谢,包括针对甲状旁腺激素的治疗,再启动骨靶向药物。
  • 生活方式干预作为低风险/潜在高回报干预,应考虑用于所有患者。

临床怎么用

  • 对 CKD G4-5D 合并骨脆性患者,采用 CKD 相关骨质疏松的诊疗框架进行个体化评估。
  • 启动骨靶向药物前,先优化矿物质代谢并针对甲状旁腺激素进行治疗。
  • 所有患者均应考虑生活方式干预。

局限性

  • 证据基于指南在绝经后女性和老年男性中广泛接受的策略,需随机对照试验在晚期 CKD 中验证。
  • 提出的治疗流程为实用性建议,待恰当设计且把握度充分的临床试验提供更明确证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fracture risk increases along the progression of chronic kidney disease (CKD) to become several-fold higher in patients with CKD G4-5D as compared to the kidney-healthy background population matched for age and sex. In 2023, Kidney Disease Improving Global Outcomes (KDIGO) introduced the term CKD-associated osteoporosis to acknowledge and emphasize the overlap in diagnostic workup and therapeutic choices when treating bone fragility in CKD versus other conditions of osteoporosis, while maintaining the need to individualize the treatment plan with knowledge of CKD. Although evidence-based practice guidelines promote management strategies that are widely accepted in postmenopausal women and elderly men, there is a clear need to perform randomized controlled trials to confirm or disprove the benefits of therapy in the setting of advanced CKD. Lifestyle modification, as a 'low risk/potentially high return' intervention, should be considered in all patients. Current evidence furthermore supports a sequential approach to treatment, where mineral metabolism should be optimized, including parathyroid hormone targeting therapy, before initiating bone targeting drugs. We review the current standards of treatment and discuss novel developments in the pathophysiology, diagnosis, outcome prediction and management of CKD-associated osteoporosis and propose a pragmatic treatment algorithm, pending more definite evidence from appropriately designed and powered clinical trials.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Evenepoel P, Jørgensen HS. CKD-associated osteoporosis in patients with CKD G4-5D: a pragmatic treatment approach. Nephrol Dial Transplant. 2026. PMID: 42566271. doi:10.1093/ndt/gfag124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。